GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,485.00p
   
  • Change Today:
    -24.00p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,293.50
  • Currency: UK Pounds
  • Shares Issued: 4,132.69m
  • Volume: 7,647,214
  • Market Cap: £61,370m
  • RiskGrade: 129
  • Beta: 0.01

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 4.1% 0.0%
Div Cover 2.6 2.6
Op Mrgn 12.8% 28.4%
ROCE 47.1%  
Latest F'cast
P/E 9.3 8.8
PEG 3.4 2.7
Pr/Revenue 2.0 1.8
Pr/Book 4.7  
Latest F'cast
Revenue 3.5% 4.6%
PBT -42.7% 167.8%
EPS 2.7% 6.0%
DPS 5.2% 307.0%

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 34,099.00 6,968.00 115.90p 14.5 n/a -6% 80.00p 4.8%
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 32,820.36 9,310.41 168.88p 8.8 1.5 +6% 65.12p 0.0%
31-Dec-26 34,550.79 10,164.82 187.40p 7.9 0.7 +11% 69.67p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Notice of AGM 24-Mar-2025 16:10 RNS
EMA Filing acceptance for Nucala COPD 24-Mar-2025 07:05 RNS
Transaction in Own Shares 24-Mar-2025 07:00 RNS

GSK ShareCast News

EMA accepts GSK's application to expand Nucala use 24-Mar-2025 ShareCast
FDA to review GSK's depemokimab 03-Mar-2025 ShareCast
London close: Stocks little changed after UK dat... 21-Feb-2025 ShareCast

GSK Top Newspaper Links

GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent
GSK to cut hundreds of US jobs 01-Dec-2014 Telegraph

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
20-Mar-25 Buy Vishal Sikka 3,029.51p 857 £25,962.86
20-Mar-25 Buy Jeannie Lee 3,029.51p 249 £7,543.47
20-Mar-25 Buy Jesse Goodman 3,029.51p 249 £7,543.47

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 1,485.00p
Change Today -24.00p
% Change -1.59 %
52 Week High 1,812.50
52 Week Low 1,293.50
Volume 7,647,214
Shares Issued 4,132.69m
Market Cap £61,370m
Beta 0.01
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.94% below the market average64.94% below the market average64.94% below the market average64.94% below the market average64.94% below the market average
27.66% below the sector average27.66% below the sector average27.66% below the sector average27.66% below the sector average27.66% below the sector average
Price Trend
5.38% above the market average5.38% above the market average5.38% above the market average5.38% above the market average5.38% above the market average
30.61% above the sector average30.61% above the sector average30.61% above the sector average30.61% above the sector average30.61% above the sector average
Income
67.12% above the market average67.12% above the market average67.12% above the market average67.12% above the market average67.12% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
49.05% below the market average49.05% below the market average49.05% below the market average49.05% below the market average49.05% below the market average
35.48% below the sector average35.48% below the sector average35.48% below the sector average35.48% below the sector average35.48% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 16
Sell 3
Strong Sell 0
Total 25
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 20-Feb-25 14-Nov-24
Paid 10-Apr-25 09-Jan-25
Amount 16.00p 15.00p

Trades for 24-Mar-2025

Time Volume / Share Price
15:46 1 @ 1,489.00p
15:46 1 @ 1,489.00p
15:46 1 @ 1,489.00p
15:46 1 @ 1,489.00p
15:42 0 @ 1,489.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page